METEORIC-HF
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction and Decreased Exercise Tolerance
INCLUSION Criteria
- Left ventricular ejection fraction (LVEF) ≤ 35%
- NYHA class II or III
- NT-proBNP ≥ 200 pg/mL
- Peak VO2 ≤ 75% of the predicted normal value with RER ≥ 1.05 on the screening
EXCLUSION Criteria
- Severe uncorrected valvular heart disease
- Paroxysmal atrial fibrillation or flutter documented within the previous 6 months requiring treatment (eg anti-coagulation or antiarrhythmic therapy), direct-current (DC) cardioversion or ablation procedure for atrial fibrillation within 6 months, or plan to attempt to restore sinus rhythm (with drug therapy, ablation, or DC cardioversion) within 6 months of randomization. Subjects with persistent atrial fibrillation and no sinus rhythm documented in the prior 6 months are permitted.
- Untreated severe ventricular arrhythmias
- (eGFR) < 30 mL/min/1.73m2
Ansprechpartner im Studienzentrum
Neurath,
Barbara
Leitung Studienambulanz (Geb. 24)
Dr.
Wachter,
Angelika
Stellv. Leitung Studienzentrum (Geb. 24)
